| Autor: |
Menezes Junior ADS; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil.; School of Medical and Life Sciences, Pontifical Catholic University of Goiás, Goiânia 74605050, Brazil., Oliveira VMR; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Oliveira IC; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., de Sousa AM; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Santana AJP; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Carvalho DPC; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Paro Piai RF; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Matos FH; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., de Paiva AM; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil., Reis GBB; Faculty of Medicine, Federal University of Goiás, Goiânia 74605020, Brazil. |
| Abstrakt: |
Saroglitazar is a novel medication for dyslipidemia, but its specific effects remain unclear. Therefore, we performed a systematic review and meta-analysis to assess the efficacy and safety of saroglitazar for managing dyslipidemia. The PubMed, Scopus, and EMBASE databases were systematically searched for randomized controlled trials (RCTs) comparing 2 and 4 mg of saroglitazar with placebos for treating dyslipidemia. A random-effects model calculated the pooled mean differences for continuous outcomes with 95% confidence intervals. The study included seven RCTs involving 1975 patients. Overall, 340 (31.0%) and 513 (46.8%) participants received 2 and 4 mg of saroglitazar, respectively; 242 (22.11%) received the placebo. The mean ages ranged from 40.2 to 62.6 years, and 436 (39.8%) were women. Compared to the control group, 4 mg of saroglitazar significantly decreased the triglyceride and low-density lipoprotein (LDL) cholesterol levels but did not affect the high-density lipoprotein cholesterol level. Furthermore, the alanine aminotransferase level significantly decreased, the creatine level significantly increased, and body weight did not differ between the groups. Finally, 4 mg of saroglitazar, compared to 2 mg, significantly lowered the triglyceride level. Saroglitazar (4 mg) may be an effective treatment, but safety concerns remain. |
